- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
Following the release of Domino’s Pizza Q2 2018 results, Peter Ramshaw, Foodservice Analyst at GlobalData, a leading data and analytics company, comments: “Domino’s second quarter 2018 financial results saw the company record its 98th consecutive quarter of positive international same store sales growth and the 20th consecutive quarter of positive domestic same store sales growth. […]
The ‘Biosimilar Action Plan’ is another FDA move designed to chase value based pricing
On Wednesday (18 July) the FDA unveiled the ‘Biosimilar Action Plan’ (BAP), which aims to promote the development and accessibility of biosimilars in the US healthcare market. Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this means for the price of branded biologic molecules: “We believe […]
J&J’s HIV therapeutic Symtuza on track for US launch in 2018 after FDA approval
Following the news (Tuesday 17th July) that J&J’s HIV therapeutic, Symtuza, has been granted marketing approval by the FDA, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “This news puts J&J’s Symtuza on track to launch in the US later this year, where it is predicted to […]
Positive Phase III results in high-risk patients expected to support FDA review process for Roche’s Xofluza
Following yesterday’s news (Tuesday 17th July) that Roche has announced positive top-line results from its Phase III trial for influenza drug, Xofluza, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “Xofluza is forecast to reach annual sales of $600m by 2024. Although the drug is on track […]
Global venture capital funding grows in the higher value and early stage bands at Q1 2018
Global venture capital investments have continued to pour into higher value bands, marking a second straight quarterly rise for the segment in Q1 2018, according to GlobalData, a leading data and analytics company. The >$500m-$1000m band witnessed a significant 191% rise from an average of 2.75 investments registered in the previous four quarters to 8 […]
Personalized medication is becoming an increasing possibility for patients, due to the use of newly developed algorithms
A long sought after objective of healthcare is to ensure that each patient receives tailored treatment for their medical situation; and now, with the use of big data and newly developed algorithms this is starting to look like a genuine possibility for patients, says GlobalData, a leading data and analytics company. A study conducted at […]
Amazon whole foods sector could play role in the prevention of chronic diseases
Chronic diseases, such as heart disease, stroke, type 2 diabetes (T2D), cancer and chronic respiratory diseases, are the most common and most costly health problems, yet they are largely preventable by lifestyle changes, says GlobalData, a leading data and analytics company. The company’s latest report: ‘PharmaPoint: Type 2 Diabetes’, reveals that 26.5 million people were […]
Exploding levels of public debt in developed economies could force some governments to declare bankruptcy, says GlobalData
The sovereign debt levels of developed countries have risen to an alarming level in recent years, posing a serious threat to their economic prospects, says GlobalData, a leading data and analytics company. The debt to GDP ratio in developed nations in 2017 was 380% compared to over 200% in the developing nations according to data […]
Amazon’s dive into healthcare could benefit patients requiring frequent medical products
Since Amazon took its strategic move of plunging into healthcare, its plans are progressively unfolding, driving down market value of many of the industry’s biggest retail pharmacies including Walgreens, CVS and Rite Aid, says GlobalData, a leading data and analytics company. The e-commerce giant, who was already selling medical supplies and equipment, and whole foods, […]
Sweden’s cross-border merger and acquisitions activity continued to grow at a rapid pace in 2017
Global inbound and outbound merger and acquisitions (M&A) activity in 2017 was characterised by the continued dominance of the US in both volume and value and Sweden’s emergence as a leading M&A nation in percentage volume growth terms, according to GlobalData, a leading data and analytics company. Outbound M&A is where a domestic company merges […]
Top 25 global consumer packaged goods companies by market cap Q1 2018
The performance highlights of the Top 25 publicly traded global consumer packaged goods companies by Market Cap (Mcap) have been analysed in the latest research from GlobalData, a leading data and analytics company. The completed day vs day (31 Mar 2018 vs 31 Dec 2017) analysis reveals a number of interesting insights. The list of […]
Recent European Medicines Agency survey findings on pharma brexit preparedness are supported by GlobalData’s own survey findings
Following today’s news (Wednesday 11th July) that a European Medicines Agency (EMA) survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view based on GlobalData’s own findings: “In results from a survey carried out by the EMA, announced […]
Merck to expand Keyruda’s indication list as they further cement themselves as a key player in cancer therapeutics
Following today’s news (Wednesday 11 July) that the FDA have accepted Merck’s supplementary biologic license application (sBLA) for monoclonal antibody Keytruda (pembrolizumab) to be used in patients suffering from advanced hepatocellular carcinoma, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what the next steps are: “Hepatocellular carcinoma […]
As Amazon’s acquisition of PillPack sends shockwaves across the pharma industry, GlobalData publish their Top 25 Global Pharmaceutical Companies analysis by Market Cap
The prospect of Amazon entering the pharma industry with the acquisition of PillPack will be a troubling development for pharma executives around the globe.
Top 25 Global Banking Institutions by Market Cap Q1 2018
The performance highlights of the Top 25 publicly traded global banking institutions by Market Cap (Mcap) for the quarter ending March 31, 2018, have been analysed in the latest research from GlobalData, a leading data and analytics company. The completed analysis revealed a number of interesting insights.
UK SIPP market to grow by £1.9bn yearly to 2020 despite rising customer complaints
The UK Self-Invested Personal Pension (SIPP) market is flourishing, with growth continuing throughout 2017. However, there has been a rise in complaints about the product mainly due to diligence failings, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘UK Self-Invested Personal Pensions 2018’ highlights that the UK SIPP market was worth […]
Positive Phase II data for Eisai and Biogen’s BAN2401 supports Amyloid precursor protein as a therapeutic target for Alzheimer’s
Following today’s news (Friday 6 July) that Eisai and Biogen have achieved positive top-line results in their Phase 2 trial for BAN2401 in Alzheimer’s patients,
GlobalData adds BioPharm Insight’s investigative journalist team to Healthcare division
Leading data and analytics company GlobalData is pleased to announce the incorporation of BioPharm Insight’s investigative journalist content into its Healthcare offering. The consolidation follows on from GlobalData’s acquisition of BioPharm Insight as part of the Infinata suite of products in April 2017. The journalist team is based in London and New York and consists […]
NICE rejection of Roche’s Ocrevus could signal more value based assessments by the regulator
The National Institute for Health and Care Excellence (NICE) has issued a negative appraisal consultation document (ACD) for Roche’s OCREVUS®▼ (ocrelizumab) in primary progressive multiple sclerosis (PPMS)– citing the high annual cost of therapy as an unacceptable burden for the NHS to bear. Despite the fact that the drug was approved by the FDA in […]
Insurance in the gig economy is a growing market and insurers must capitalize on the opportunity
The UK insurance market has seen the emergence of the gig economy as an opportunity not only for employment purposes but also as a new and growing market. With 2.8 million individuals working within the gig economy, those who are quick to scale in the market will undoubtedly reap the benefits, according to GlobalData, a […]